Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

462 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thrombin Generation and D-Dimer for Prediction of Disease Progression and Mortality in Patients with Metastatic Gastrointestinal Cancer.
Giaccherini C, Verzeroli C, Russo L, Gamba S, Tartari CJ, Bolognini S, Schieppati F, Ticozzi C, Sarmiento R, Celio L, Masci G, Tondini C, Petrelli F, Giuliani F, D'Alessio A, De Braud F, Santoro A, Labianca R, Gasparini G, Marchetti M, Falanga A; HYPERCAN Investigators. Giaccherini C, et al. Among authors: giuliani f. Cancers (Basel). 2022 Sep 6;14(18):4347. doi: 10.3390/cancers14184347. Cancers (Basel). 2022. PMID: 36139507 Free PMC article.
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?
Giampieri R, Caporale M, Pietrantonio F, De Braud F, Negri FV, Giuliani F, Pusceddu V, Demurtas L, Restivo A, Fontanella C, Aprile G, Cascinu S, Scartozzi M. Giampieri R, et al. Among authors: giuliani f. Crit Rev Oncol Hematol. 2016 Apr;100:99-106. doi: 10.1016/j.critrevonc.2016.02.005. Epub 2016 Feb 12. Crit Rev Oncol Hematol. 2016. PMID: 26907512 Review.
Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer.
Giaccherini C, Marchetti M, Masci G, Verzeroli C, Russo L, Celio L, Sarmiento R, Gamba S, Tartari CJ, Diani E, Vignoli A, Malighetti P, Spinelli D, Tondini C, Barni S, Giuliani F, Petrelli F, D'Alessio A, Gasparini G, De Braud F, Santoro A, Labianca R, Falanga A; HYPERCAN Investigators. Giaccherini C, et al. Among authors: giuliani f. Haematologica. 2020 Jun;105(6):1704-1711. doi: 10.3324/haematol.2019.228981. Epub 2019 Sep 26. Haematologica. 2020. PMID: 31558668 Free PMC article.
Thrombin generation predicts early recurrence in breast cancer patients.
Marchetti M, Giaccherini C, Masci G, Verzeroli C, Russo L, Celio L, Sarmiento R, Gamba S, Tartari CJ, Diani E, Vignoli A, Malighetti P, Spinelli D, Kuderer NM, Nichetti F, Minelli M, Tondini C, Barni S, Giuliani F, Petrelli F, D'Alessio A, Gasparini G, Labianca R, Santoro A, De Braud F, Falanga A; HYPERCAN Investigators. Marchetti M, et al. Among authors: giuliani f. J Thromb Haemost. 2020 Sep;18(9):2220-2231. doi: 10.1111/jth.14891. Epub 2020 Aug 11. J Thromb Haemost. 2020. PMID: 32397009 Free article.
Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence.
Gomez-Rosas P, Pesenti M, Verzeroli C, Giaccherini C, Russo L, Sarmiento R, Masci G, Celio L, Minelli M, Gamba S, Tartari CJ, Tondini C, Giuliani F, Petrelli F, D'Alessio A, Gasparini G, Labianca R, Santoro A, De Braud F, Marchetti M, Falanga A; HYPERCAN Investigators. Gomez-Rosas P, et al. Among authors: giuliani f. TH Open. 2021 Feb 10;5(1):e56-e65. doi: 10.1055/s-0040-1722609. eCollection 2021 Jan. TH Open. 2021. PMID: 33585786 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 35643643
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.
Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F; Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Colucci G, et al. Among authors: giuliani f. J Clin Oncol. 2010 Apr 1;28(10):1645-51. doi: 10.1200/JCO.2009.25.4433. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194854 Clinical Trial.
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassineti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F. Di Bartolomeo M, et al. Among authors: giuliani f. BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3. BMC Cancer. 2019. PMID: 30922323 Free PMC article. Clinical Trial.
Cetuximab in colon cancer.
Giuliani F, Colucci G. Giuliani F, et al. Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S62-70. Int J Biol Markers. 2007. PMID: 17520583 Review.
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G, Giuliani F, Garufi C, Mattioli R, Manzione L, Russo A, Lopez M, Parrella P, Tommasi S, Copetti M, Daniele B, Pisconti S, Tuveri G, Silvestris N, Maiello E. Colucci G, et al. Among authors: giuliani f. Oncology. 2010;79(5-6):415-22. doi: 10.1159/000323279. Epub 2011 Apr 7. Oncology. 2010. PMID: 21474966 Clinical Trial.
462 results